highly significantp < 0.001
According to DOT per 1 000 patient-days, there was a highly significant decrease in consumption of ceftriaxone and levofloxacin, by 19.1% (p < 0.001) and 49.9% (p < 0.001), respectively ( Table 2 ).
According to DOT per 1 000 patient-days, there was a highly significant decrease in consumption of ceftriaxone and levofloxacin, by 19.1% (p < 0.001) and 49.9% (p < 0.001), respectively ( Table 2 ).